The Race for Personalized mRNA Cancer Vaccines: Phase 3 Trials Aim to Transform Melanoma and Lung Cancer Treatment
Key Facts Global Phase 3 Trials: Melanoma Leads the Way The first personalized mRNA cancer vaccine to reach Phase 3 is Moderna’s mRNA-4157 (V940) in melanoma – a groundbreaking collaboration with Merck that has quickly become a bellwether for the field. Melanoma